Spots Global Cancer Trial Database for Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Official Title: Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Study ID: NCT00717756
Conditions
Interventions
Study Description
Brief Summary: This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.
Detailed Description: This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Montefiore Medical Center, Bronx, New York, United States
Memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States
Lifespan Hospitals, Providence, Rhode Island, United States
Contact Details
Name: Howard Safran, MD
Affiliation: Brown University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
